Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 737-742

  Brautbar, Ariel ^a   Covarrubias, Daniel ^a   Belmont, John ^a   Lara Garduno, Fremiet ^a   Virani, Salim S ^a,b,c   Jones, Peter H ^a,b   Leal, Suzanne M ^a   Ballantyne, Christie M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Combination therapy; Genetic variants; Mixed dyslipidemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A5; CHOLINE FENOFIBRATE; FENOFIBRIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED DYSLIPIDEMIA; MULTICENTER STUDY; POPULATION; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS A; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 82955247614     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.08.015     Document Type: Article

References (29)

1. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
2. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
3. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
4. Lai C.Q., Arnett D.K., Corella D., et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol 2007, 27:1417-1425.
5. Wojczynski M.K., Gao G., Borecki I., et al. ApolipoproteinB genetic variants modify the response to fenofibrate: a GOLDN study. J Lipid Res 2010, 51:3316-3323.
6. Perez-Martinez P., Corella D., Shen J., et al. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Am J Clin Nutr 2009, 89:391-399.
7. Jones P.H., Bays H.E., Davidson M.H., et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin Drug Investig 2008, 28:625-634.
8. Jones P.H., Davidson M.H., Kashyap M.L., et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009, 204:208-215.
9. van Raalte D.H., Li M., Pritchard P.H., Wasan K.M. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 2004, 21:1531-1538.
10. Havel R.J., Kane J.P. Introduction: structure and metabolism of plasma lipoproteins. Metabolic and molecular bases of inherited disease 2001, McGraw-Hill, New York. http://www.ommbid.com/, 8th ed. D. Valle, A.L. Beaudet, B. Vogelstein, K.W. Kinzler, S.E. Antonarakis, A. Ballabio (Eds.).
11. Kathiresan S., Willer C.J., Peloso G.M., et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009, 41:56-65.
12. Willer C.J., Sanna S., Jackson A.U., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008, 40:161-169.
13. Spirin V., Schmidt S., Pertsemlidis A., Cooper R.S., Cohen J.C., Sunyaev S.R. Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol. Am J Hum Genet 2007, 81:1298-1303.
14. Thompson A., Di Angelantonio E., Sarwar N., et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008, 299:2777-2788.
15. Seldin M.F., Shigeta R., Villoslada P., et al. European population substructure: clustering of northern and southern populations. PLoS Genet 2006, 2:e143.
16. Purcell S., Neale B., Todd-Brown K., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81:559-575.
17. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005, 45:1649-1653.
18. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002, 25:1198-1202.
19. Grundy S.M., Vega G.L., Yuan Z., Battisti W.P., Brady W.E., Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005, 95:462-468.
20. Vega G.L., Ma P.T., Cater N.B., et al. Effects of adding fenofibrate (200mg/day) to simvastatin (10mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003, 91:956-960.
21. Olivier M., Wang X., Cole R., et al. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 2004, 83:912-923.
22. Pennacchio L.A., Olivier M., Hubacek J.A., Krauss R.M., Rubin E.M., Cohen J.C. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002, 11:3031-3038.
23. Wang J., Ban M.R., Kennedy B.A., et al. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med 2008, 5:730-737.
24. Johansen C.T., Wang J., Lanktree M.B., et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010, 42:684-687.
25. Palmen J., Smith A.J., Dorfmeister B., Putt W., Humphries S.E., Talmud P.J. The functional interaction on in vitro gene expression of APOA5 SNPs, defining haplotype APOA52, and their paradoxical association with plasma triglyceride but not plasma apoAV levels. Biochim Biophys Acta 2008, 1782:447-452.
26. Sarwar N., Sandhu M.S., Ricketts S.L., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639.
27. Pennacchio L.A., Olivier M., Hubacek J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173.
28. Elosua R., Ordovas J.M., Cupples L.A., et al. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res 2006, 47:990-996.
29. Laurila P.P., Naukkarinen J., Kristiansson K., et al. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:346-352.